Vivos Therapeutics
VVOS
24 hedge funds and large institutions have $2.15M invested in Vivos Therapeutics in 2026 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 2 closing their positions.
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
61% more capital invested
Capital invested by funds: $1.34M → $2.15M (+$811K)
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
26% more funds holding
Funds holding: 19 → 24 (+5)
10.09% more ownership
Funds ownership: 7.32% → 17.41% (+10%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$1.79M |
| 2 |
IWM
IHT Wealth Management
Chicago,
Illinois
|
+$65.8K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$62.9K |
| 4 |
CWM
Centurion Wealth Management
Mclean,
Virginia
|
+$57.2K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$40.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
-$235K |
| 2 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$8.76K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$2.61K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$267 |
VVOS Hedge Fund Activity: Q1 2026 in Review
24 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Vivos Therapeutics (VVOS) for Q1 2026, worth a combined $2.15M — up 61% from $1.34M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new VVOS positions and 2 closed out — a net gain of 6 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.79M. The largest seller was DRW Securities, exiting entirely with an estimated $235K sold.
- 24 institutional investors held Vivos Therapeutics (VVOS) as of Q1 2026, up from 19 in Q4 2025.
- Funds reported $2.15M of Vivos Therapeutics stock for Q1 2026, up 61% quarter-over-quarter.
- 8 funds opened new Vivos Therapeutics positions in Q1 2026 and 2 closed out, a net change of +6 holders.
- The largest Vivos Therapeutics buyer in Q1 2026 was Armistice Capital, an estimated $1.79M added.
- The largest Vivos Therapeutics seller in Q1 2026 was DRW Securities, an estimated $235K sold.
Based on aggregated 13F filings for Q1 2026.